Placenta-derived trophoblast extracellular vesicles promote CD169+ macrophage migration and suppress ovarian tumour growth
A lower survival rate due to a later stage of diagnosis requires a more effective therapy for ovarian cancer. Extracellular vesicles (EVs) have shown therapeutic potential in various diseases, partly due to their ability to modulate immune responses. We previously showed that placental-derived trophoblast EVs suppressed ovarian tumour growth, accompanied by increased infiltration of CD169 SKOV-3 ovarian cancer cell xenografts were intraperitoneally injected with placental-derived trophoblast EVs. Tumour growth was monitored, and EV biodistribution was tracked at four time points. Additionally, the dynamics of CD169 A reduction of tumour growth after EV treatment was observed. At early time points (within 24 hours), trophoblast EVs preferentially accumulated in immune organs, including the inguinal lymph nodes, but not in tumours. The significantly higher intensity of CD169 Placental-derived trophoblast EVs may act as an immune modulator, specifically in the presence of tumours, through promoting CD169